IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
US7781404B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 26, 2009 |
| Grant date | Aug 24, 2010 |
| Priority date | — |
| Expiry date | Feb 26, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.